Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
M. Di Maio
Institutions:
Azienda Ospedaliera Citta' della Salute e della Scienza di Torino,
University of Turin
Observed institutions:
Azienda Ospedaliera Citta' della Salute e della Scienza di Torino,
A. O. Ordine Mauriziano di Torino,
University of Turin
ORCID:
0000-0001-8906-3785
Observed ORCID:
0000-0001-8906-3785
OpenAlex ID:
A5021974197
Glycemic control and cancer outcomes in oncologic patients with diabetes: an Italian Association of Medical Oncology (AIOM), Italian Association of Medical Diabetologists (AMD), Italian Society of Diabetology (SID), Italian Society of Endocrinology (SIE), Italian Society of Pharmacology (SIF) multidisciplinary critical view
2024
·
A. Natalicchio
, N. Marrano
, et al.
·
Journal of Endocrinological Investigation
·
33
PDF
Predicting early recurrence after resection of initially unresectable colorectal liver metastases: the role of baseline and pre-surgery clinical, radiological and molecular factors in a real-life multicentre experience
2024
·
R. Moretto
, M.M. Germani
, et al.
·
ESMO Open
·
18
PDF
Sexual health in cancer care: a narrative review and position statement from the Italian Association of Medical Oncology (AIOM)
2025
·
A. Rossi
, A.G. Leone
, et al.
·
ESMO Open
·
17
PDF
Comprehensive genomic profiling by liquid biopsy portrays metastatic colorectal cancer mutational landscape to predict antitumor efficacy of FOLFIRI plus cetuximab in the CAPRI-2 GOIM trial
2025
·
D. Ciardiello
, L. Boscolo Bielo
, et al.
·
ESMO Open
·
15
Clinical practice guidelines for the management of non-functioning advanced GEP-NENs: a GRADE approach for evidence evaluation and recommendations by the Italian Association of Medical Oncology (AIOM) in collaboration with the Italian Association for Neuroendocrine Tumors (ITANET)
2025
·
F. Spada
, F. Gelsomino
, et al.
·
ESMO Open
·
4
Systematic review of adverse events reporting in clinical trials leading to approval of targeted therapy and immunotherapy
2016
·
P. Bossi
, L. Botta
, et al.
·
Annals of Oncology
·
3
Corrigendum to “Under-reporting of subjective symptoms and its prognostic value: a pooled analysis of 12 cancer clinical trials”
2024
·
L. Arenare
, R. Di Liello
, et al.
·
ESMO Open
·
2
Metformin impact on progression-free survival in diabetic patients with advanced pancreatic neuroendocrine tumors (pNET) receiving everolimus and/or somatostatin analogues. The PRIME-NET (Pancreatic multicentric, Retrospective, Italian MEtformin) study
2016
·
S. Pusceddu
, R. Marconcini
, et al.
·
Annals of Oncology
·
2
3166eP Mapping the regulatory landscape of phase I oncology trials in the EU: Key insights from CTIS
2025
·
S. Stabile
, C. Citterio
, et al.
·
Annals of Oncology
·
1
590P Ki67 as a predictor of response to PARP inhibitors in platinum sensitive BRCA wild type ovarian cancers: MITO 37 retrospective study
2022
·
V. Tuninetti
, E. Ghisoni
, et al.
·
Annals of Oncology
·
1
3648eP Multiomics approach in metastatic clear cell RCC (MeetUro 31): Preliminary analysis of trascriptomic features - A Meet-URO and AIRC study
2026
·
E. Verzoni
, M. Stellato
, et al.
·
Annals of Oncology
520P Enriching for pathogenic germline variants (PGVs) in lung cancer (LC): A systematic review of patient selection strategies
2026
·
F. Citarella
, R. Ferrara
, et al.
·
ESMO Open
PDF
302P Real-world attrition in neoadjuvant and perioperative immunotherapy-based treatment protocols in patients with locally-advanced non-small cell lung cancer: A multicenter national study
2026
·
F. Guerrera
, P. Bertoglio
, et al.
·
ESMO Open
369P Family history of cancer (FHC) in non-small cell lung cancer (NSCLC): A cross-sectional-prospective study to guide germline referral
2026
·
F. Citarella
, F.M. Venanzi
, et al.
·
ESMO Open
PDF
WITHDRAWN: 2726P Real-world versus trial populations in metastatic soft tissue sarcomas: A comparative analysis of AIFA monitoring registries and clinical trials of trabectedin and pazopanib
2025
·
A. Mazzocca
, S. Celant
, et al.
·
Annals of Oncology
3152P Compliance with health-related quality of life (QoL) questionnaires in clinical trials conducted in patients with advanced cancer: A meta-research study
2025
·
D.L. Bellino
, V. Tuninetti
, et al.
·
Annals of Oncology
745P Estimating the clinical benefit of the secondary resection of metastases in liver-limited metastatic colorectal cancer: An individual patient data-based pooled analysis of nine randomized trials
2025
·
A. Taravella
, M.M. Germani
, et al.
·
Annals of Oncology
3153P Health-related quality of life assessment and results in clinical trials testing new cancer drugs approved by the European Medicines Agency (EMA) between 2019 and 2024
2025
·
G.A. Intilisano
, M. Audisio
, et al.
·
Annals of Oncology
2342P IN.C.L.U.D.E.: An Italian study on inclusion of LGBTQIA+ oncology healthcare professionals and equity dynamics in the workplace
2025
·
L. Belluomini
, G. Viscardi
, et al.
·
Annals of Oncology
27P: Impact of platinum-based chemotherapy (CT) on acquired resistance (AR) to first-line immunecheckpoint inhibitors (ICI) in non-small cell lung cancer (NSCLC): Individual patient data metanalysis
2025
·
S. Oresti
, F. Salomone
, et al.
·
Journal of Thoracic Oncology
PDF
1626P Time trends (2012-2016 vs 2017-2021) in health-related quality of life (QoL) assessment and reporting in oncology: A systematic review of randomized phase III trials
2022
·
L. Marandino
, F. Trastu
, et al.
·
Annals of Oncology
Dissecting primary resistance to anti-EGFRs in RAS and BRAF wt metastatic colorectal cancer (mCRC): A case-control study
2017
·
D. Rossini
, C. Cremolini
, et al.
·
Annals of Oncology
PDF
Show more works
View as search
Works count:
22
Citation count:
95
H-index:
4
I10-index:
4
Year
Topic
Type